Promethean Share Discussion Threads

[propane] 27/4/2003 13:58

The Sunday Times - Business



April 27, 2003

Sharewatch: Lost without Dolly



PPL Therapeutics: it will take a miracle of Dolly the sheep proportions to revive the Midlothian company's fortunes. The loss-making drug development firm is struggling for cash. Its products (including AAT, a potential treatment for emphysema) are still miles from market, and it is selling the only star in its ailing universe, the world-class regenerative medicines business, which clones piglets to "grow" replacement human organs. PPL's shares have crashed from a 52-week high of 30p to 6p, prompting a recent campaign from Paul Scott, a rebel shareholder, to call for the company to be shut down. Meanwhile, the firm's German development partner and 4% shareholder, Bayer, is saddled with litigation following the withdrawal of its cholesterol-lowering drug, Baycol, which is suspected of being linked to the deaths of 100 of the 6m patients it was prescribed to. PPL is expected to post full-year losses on Monday of between £11m and £14m, against a loss of £14.25m last year. Enough to make poor Dolly turn in her grave.

[qazwsx123] 22/4/2003 00:01

If you are interested in biotechs, you may be interested in the expected news from Alizyme (AZM) as follows:

1) May 2003: PIIb results for Renzapride treating c-IBS (514 patients).
2) Mid 2003: first licensing deal for Colal-Pred.
3) Oct 2003: PIIb results for Renzapride treating m-IBS (170 patients).
4) Oct 2003: PIIb results for ATL-962 treating obesity (340 patients).
5) H2 2003: PIIa results for ATL-104 treating mucositis.
6) Q4 2003: further pharmacokinetic/dynamic results for Renzapride (48 patients in USA).
------------------------------------------------------------------------------
7) 2004: licensing deals for Renzapride treating c-IBS & m-IBS.
8) 2004: licensing deal for ATL-962 treating obesity.
9) H2 2004: PIII results for Colal-Pred (active disease and remission trials).
------------------------------------------------------------------------------
10) H1 2005: Colal-Pred on market.

Sales of Colal-Pred treating active ulcerative colitis should exceed £100m pa, as should sales for maintaining remission; generating revenues of approximately £30 million pa for the Company (i.e. 15% royalties on annual sales of approximately £200 million) (Investor's Chronicle suggested 30% royalties, but that may be on the high side).

Sales of Renzapride, ATL-962 and ATL-104, should generate much higher revenues for Alizyme.

Brett Pollard of analysts Seymour Pierce estimates the licensing deals anticipated for Colal-Pred, Renzapride and ATL-962, during 2003/04, could bring in £50 million cash.

[landsker] 11/4/2003 17:38

its about time people started phoning up their head office and hassling them its the only way they will get the message,

[dell314] 11/4/2003 11:35

Gazza - You seem to be ignoring the fact that the board still don't appear to have a credible survival plan. They seem totally oblivious to the reality that they don't have the cash to complete their plans. During the biotech boom, I think these guys thought they could get away with paying themselves hefty salaries for ever, whilst returning to the city and shareholders for a cash top-up every so often.
They need to come up with a survival plan quickly or they may as well pack up now and return cash to shareholders....

[gazzabutty] 11/4/2003 11:25

patience will pay off soon. By the end of april, may perhaps, when the agm takes place. Then we'll see change.

G

[gazzabutty] 11/4/2003 11:24

Good news, still no price change.

[eugene1234] 10/4/2003 07:57

AFX) - PPL Therapeutics PLC, the company behind Dolly the cloned
sheep, said it has agreed to sell its US regenerative medicines business to
Regenecor Holdings Inc for preferred stock representing 22.2 pct of the US
company, worth 1 mln usd.
PPL will also be reimbursed operating expenses incurred during 2003.
The Regenerative Medicine Business comprises PPL Therapeutics Inc, which is
engaged in the development of xenograft, stem cell and polyclonal antibody
programmes in the US.
The disposal is in line with PPL's strategy of focusing on its core business
of developing and producing therapeutic proteins.
Regenecor is a new company formed by University of Pittsburgh Medical Center
and biotech venture capital groups specifically for this transaction. The
founders have subscribed a total of 3.5 mln usd million for Regenecor Series A
Preferred Stock. This funding is expected to last for 18 months research and
development.
PPL is not compelled to participate in any future fund raising.
The Regenerative Medicine Business had net assets last June of 600,000 stg,
and in the six months to June reported operating costs of 1.0 mln stg and a
pretax loss of 500,000 stg.
email: newsdesk@afxnews

[mrx001] 07/4/2003 23:21

They have a legal requirement to publish before the end of April!!

[james8] 07/4/2003 15:37

PPL told MrX001 on TMF that results would be later this month but an exact date had not been set.(I don't think that they have to give a warning)

[vpmd7afto] 07/4/2003 15:18

Anybody know if there is any law's regarding when the AGM or results have to be?
Could they delay them 6 months?

[the name is bond] 07/4/2003 14:41

Yr end results overdue now, they were published mid March last year.
Strange not even a date for results yet !!

[vpmd7afto] 07/4/2003 13:19

Yeah com'on PPL give us an AGM date.Need something to look forward to/dread.....
VP

[gazzabutty] 05/4/2003 20:27

like watching paint dry, only more tedious.

PPL need a kick up the ass.

G

[islam] 28/3/2003 14:00

says end of next month on link provided by dell314

[the carpenter] 25/3/2003 10:51

When are the results due?

[dell314] 24/3/2003 11:09

News report on the action group and Paul's response:

[karmicpete] 17/3/2003 01:08

There is an update on the PPL action group site tonight:



Cheers

Pete

[hereshoping] 12/3/2003 11:11

Its all very quiet
Still no news from the board
Price is dropping again
No news from Metage...I presume they are in discussion with the board
Presumably the board are sticking to their guns,and I would think that if they continue with their ridiculous stance Metage will dump their holding
A blatant case of mis management..Roll on egm...Roll on cbi enquiry

[bigbadgar] 11/3/2003 16:09

im guessing its because we dont pay for that feature although it has alerted us that something has been said on the premium boards, which sounded v promising!

G

[bigbadgar] 10/3/2003 19:47

i know
weird?

G

[vpmd7afto] 10/3/2003 11:44

Whats the premium board thread about? I can't get it.

[bigbadgar] 09/3/2003 18:15

its gone so quiet, why?

[james8] 28/2/2003 10:12

Update of site:-

[ccraig69] 26/2/2003 00:55

Trying to increase cash bun, recruting staff
Check it out on the website

Surley they should be trying to reduce costs to make them money go further..